E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Initial diagnosis of histologically confirmed follicular lymphoma |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10016903 |
E.1.2 | Term | Follicle centre lymphomas, follicular grade I, II, III |
E.1.2 | System Organ Class | 100000004851 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the complete response rate according to Cheson criteria 1999 after a short induction treatment by Rituximab and Bendamustine in 1st line follicular lymphoma patients, ≥ 60 years old, with an intermediate or high FLIPI score, and without high tumor burden (according to GELF criteria) |
|
E.2.2 | Secondary objectives of the trial |
- Complete response rate at the end of induction according to Cheson 2007
- Overall response rates at the end of induction phase
- Overall response rate at the end of induction phase according to Cheson 2007
- Response rates at the end of maintenance phase according to Cheson 1999
- Response rates at the end of maintenance phase according toCheson 2007
- Duration of response
- Progression free survival
- Overall survival
- Time to next anti lymphoma treatment
- Immediate toxicity (grades 3 and 4, during the twelve first weeks)
- Long-term toxicity
- QoL evaluation
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Predictive value or early response evaluated at week 12 by 18FDG-TEPStudy |
|
E.3 | Principal inclusion criteria |
• Histologically confirmed follicular lymphoma CD20+, all grades except the grade 3b with a lymph node biopsy performed within 6 months before study entry and with material available for central review
• A minimal initial immunology is required, including : CD20, bcl-2, CD10 et CD5
• Age must be ≥ 60 years.
• Patients not previously treated.
• Patients with an intermediate or high risk FLIPI score requiring with one or more of the following adverse prognostic factors:
1. Ann Arbor Stage (I-II vs. III-IV)
2. Hemoglobin level ( < 12g/dL vs. ≥ 12 g/dL)
3. Number of nodal areas (< 5 vs. ≥ 5)
• Patients with at least one measurable site of disease: patients with only blood or marrow or splenic infiltration are excluded
• Performance status ≤ 2 on the ECOG scale
• Adequate hematological function (unless abnormalities are related to lymphoma infiltration of the bone marrow) including:
Hemoglobin ≥ 8.0 g/dL (5.0 mmol/L)
Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
Platelet count ≥ 100 x 109/L
• Adequate renal function: calculated creatinine clearance > 50 ml/min (according to MDRD method) unless these abnormalities are related to lymphoma
• Adequate hepatic function: Total bilirubin < 2.0 mg/dl (34 µmol/L), AST (SGOT) and ALT (SGPT) ≤ 2.5 x the upper limit of normal unless these abnormalities are related to lymphoma
• Adequate cardiac function: LEVF ≥ 50% calculated by echocardiography or scintigraphy
• Having previously signed a written informed consent
|
|
E.4 | Principal exclusion criteria |
• Other histological types of lymphoma than follicular lymphoma
• Grade 3b follicular lymphoma
• Patients previously on watch and wait since more than 6 months from diagnosis
• Patients previously treated for lymphoma, except splenectomy
• Bulky disease at study entry according to the GELF criteria
• Presence or history of CNS disease (either CNS lymphoma or lymphomatous meningitis)
• Patients with prior or concomitant malignancies except non-melanoma skin cancer or adequately treated in situ cervical cancer or previous cancer in CR without any treatment in the last 5 years
• Known HIV infection or active HBV or HCV infection
• Poor Performance status > 2 on the ECOG scale
• Known contra-indication to study product
• Serious underlying medical conditions, which could impair the ability of the patient to participate in the trial (e.g. ongoing infection, uncontrolled diabetes mellitus, gastric ulcers, active autoimmune disease).
• Any other co-existing medical or psychological condition that will preclude participation in the study or compromise ability to give informed consent.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
To evaluate the response rate after a short treatment by rituximab and bendamustine instead of a watch-and-wait approach. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
After the completion of the induction phase for all the 62 included patients |
|
E.5.2 | Secondary end point(s) |
- Complete response rate at the end of induction according to Cheson 2007
- Overall response rates at the end of induction phase according to Cheson 1999
- Overall response rate at the end of induction phase according to Cheson 2007
- Response rates at the end of maintenance phase according to Cheson 1999
- Response rates at the end of maintenance phase according toCheson 2007
- Duration of response
- Progression free survival
- Overall survival
- Time to next anti lymphoma treatment
- Immediate toxicity (grades 3 and 4, during the twelve first weeks)
- Long-term toxicity
- QoL evaluation
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- After the completion of the induction phase for all the 62 included patients
- After the completion of the maintenance phase for all the 62 included patients |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 94 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 111 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 9 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 9 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |